INmune Bio, Inc. (NASDAQ:INMB) Receives Average Recommendation of “Hold” from Brokerages

INmune Bio, Inc. (NASDAQ:INMB) has been given a consensus recommendation of “Hold” by the six research firms that are presently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation, one has given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $8.00.

A number of analysts have issued reports on the stock. Wall Street Zen downgraded shares of INmune Bio from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Lucid Cap Mkts upgraded shares of INmune Bio from a “hold” rating to a “strong-buy” rating in a report on Wednesday, March 11th.

Institutional Trading of INmune Bio

A number of large investors have recently made changes to their positions in INMB. Quadrature Capital Ltd bought a new stake in shares of INmune Bio in the 4th quarter worth about $26,000. Intech Investment Management LLC bought a new stake in shares of INmune Bio in the 2nd quarter worth about $26,000. Cary Street Partners Financial LLC bought a new stake in shares of INmune Bio in the 3rd quarter worth about $29,000. Independent Advisor Alliance bought a new stake in shares of INmune Bio in the 3rd quarter worth about $30,000. Finally, Squarepoint Ops LLC bought a new stake in shares of INmune Bio in the 3rd quarter worth about $30,000. 12.72% of the stock is currently owned by institutional investors.

INmune Bio Stock Performance

INMB opened at $1.43 on Friday. INmune Bio has a fifty-two week low of $1.09 and a fifty-two week high of $11.64. The firm’s fifty day moving average is $1.34 and its 200 day moving average is $1.50. The stock has a market cap of $38.01 million, a price-to-earnings ratio of -0.86 and a beta of 1.04.

INmune Bio (NASDAQ:INMB) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.04.

INmune Bio Company Profile

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.